AstraZeneca (AZN) said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer.
The company said its combination therapy reduced the risk of disease progression or death by 56% compared with standard treatment, with patients experiencing a median progression-free survival of 16 months versus 9.2 months for standard-of-care treatment.
The drugmaker said its therapy also delayed quality-of-life deterioration and pain.
AstraZeneca said data for key secondary endpoints of time to second disease progression and overall survival were immature at the time of the interim analysis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.